Avivagen Inc VIVXF

publication in the New Zealand Veterinary Journal

[StoneMan45]

Avivagen Announces the Publication of its New Zealand OxC-beta^TM Livestock Dairy Trial for Use Against Sub-Clinical Mastitis

Ottawa, ON / Business Wire / February 18, 2021 / – Avivagen Inc.  (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely support immune function, thereby supporting general health and performance, is pleased to announce that a paper “Evaluation of fully oxidized β-carotene as a feed ingredient to reduce bacterial infection and somatic cell counts in cows with subclinical mastitis” reporting an independent trial conducted in New Zealand by Dr. Scott McDougall has been accepted for publication in the New Zealand Veterinary Journal. A preprint of the paper is available at: https://www.biorxiv.org/content/10.1101/2020.10.12.335463v1.full
 
Avivagen previously reported the positive outcome of the trial to shareholders in a press release on February 24, 2020. The two seminal findings of the trial were that treatment with OxC-beta:

• Resulted in a 100% increase in the number of udder-quarters testing negative  for the presence of bacteria in milk at the end of the 42-day study.
• Significantly reduced the number of udder-quarters that progressed from subclinical to full clinical mastitis.

 
The New Zealand Veterinary Journal (NZVJ) is an international journal publishing high quality peer-reviewed articles covering all aspects of veterinary science. It ranks in the top 25% of veterinary science journals in the world. The acceptance and publication of the manuscript in NZVJ provides scientific validation of the trial and its findings which is important to Avivagen’s customers.

Avivagen has already successfully leveraged the results of the New Zealand trial with dairy customers in Mexico leading to a multi-tonne order of OxC-beta. Publication in the peer-reviewed NZVJ will further increase the value of the results with potential customers in several important dairy markets around the world.
 
Mastitis is one of the costliest diseases for treatment in the dairy industry, as animals infected with mastitis must be treated by antibiotics, requiring that the infected dairy cows be removed from milk production until fully healthy in order to ensure that their milk does not contain antibiotics.